Clinical trials: Disorder, Mood
Major Depressive Disorder
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01436162
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate )
- Where
- 101 sites in United States, Belgium and 9 more
- Volunteers
- 1,105 people
- Sponsor
- Shire
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER compared to placebo in patients with Major Depressive Disorder (MDD).
- Trial name
- NCT01377194
- Testing
- Levomilnacipran ER
- Where
- 51 sites in United States, Canada
- Volunteers
- 568 people
- Sponsor
- Forest Laboratories
Stress, Anxiety
The Effects of Smell on Mood and Physical Responses
The purpose of this study is to examine the body's response to relaxing and stimulating fragrances commonly used in aromatherapy.
- Conditions
- Stress, Anxiety, Depression
- Trial name
- NCT00097253
- Testing
- Exposure to relaxant and stimulant odors
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Bipolar Disorder
Risperidone and Divalproex Sodium With MRI Assessment in Pediatric Bipolar
The study is to examine the null hypothesis that risperidone and divalproex sodium are equally effective in treating/stabilizing pediatric bipolar disorder.
- Trial name
- NCT00176202
- Testing
- Divalproex Sodium, risperidone
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- University of Illinois Chicago
Treatment Resistant Depression
Pharmacogenomics for Antidepressant Guidance and Education
More than one out of three individuals treated for major depressive disorder (MDD) do not experience a full reduction of symptoms even when treated with adequate antidepressant medication.
- Trial name
- NCT01555021
- Testing
- Genotyping assays
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Combining Medications to Enhance Depression Outcomes
This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or recurrent major depressive disorder.
- Trial name
- CO-MED (NCT00590863)
- Testing
- Escitalopram + Bupropion SR, Venlafaxine XR + Mirtazapine
- Where
- 15 sites in United States
- Volunteers
- 665 people
- Sponsor
- National Institute of Mental Health (NIMH)
Mood Disturbance, Mood Disorders
A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth
This study consists of a 6-week, open-label, randomized clinical trial study to compare efficacy and tolerability of the natural treatments omega-3 fatty acids, inositol, and N-acetylcysteine (NAC) in the treatment of mood…
- Conditions
- Mood Disturbance, Mood Disorders, Natural Supplements, Alternative Treatment
- Trial name
- NCT03911414
- Testing
- Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as a monotherapy for Major Depressive Disorder.
- Trial name
- Reliance III (NCT05081167)
- Testing
- REL-1017
- Where
- 10 sites in United States
- Volunteers
- 232 people
- Sponsor
- Relmada Therapeutics, Inc.
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Major Depressive Disorder
Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Major depressive disorder (MDD) is highly prevalent and nearly 70% of individuals with MDD do not respond to standard antidepressant therapies despite adequate dosing.
- Trial name
- NCT02900092
- Testing
- Ganaxolone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive Disorder
This study will evaluate the long-term safety and tolerability of escitalopram (Lexapro) in children 7 to 11 years of age with major depressive disorder (MDD).
- Trial name
- NCT01198795
- Testing
- Escitalopram
- Where
- 16 sites in United States
- Volunteers
- 162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder, Treatment-Resistant Depression
Antidepressant Effects of TS-161 in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a common, chronic mental illness. It can take weeks to months for antidepressants to work. Researchers want to test a new drug that might act more rapidly.
- Conditions
- Major Depressive Disorder, Treatment-Resistant Depression, Depression
- Trial name
- NCT04821271
- Testing
- TS-161
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, MDD
Mechanism of Action of tACS for the Treatment of MDD
The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with EEG) and mood…
- Trial name
- GLADIATOR2 (NCT03994081)
- Testing
- tACS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of North Carolina, Chapel Hill
Bipolar Disorder, Cognitive Impairment
Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder
Quetiapine has been reported to have beneficial cognitive effects in several randomized controlled trials in schizophrenia. It has not yet been studied in bipolar disorder, but promising results from the use of extended release…
- Trial name
- NCT00746421
- Testing
- Quetiapine XR
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Emory University
Major Depressive Disorder, Posttraumatic Stress Disorder
Comparing Group Therapies for Veterans With Depression and PTSD
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective psychotherapy for individuals with depressive and PTSD. However, CBT is largely underutilized within Veteran Affairs Medical Centers (VAMCs) due to the cost…
- Trial name
- NCT03979040
- Testing
- Group Transdiagnostic Behavior Therapy, Group Disorder-Specific Therapy (G-DSTs)
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- VA Office of Research and Development
Bipolar Disorder
Comparative Effectiveness Study for Bipolar Disorder
The purpose of this study is to compare the effectiveness of lithium and quetiapine for the treatment of individuals with bipolar disorder.
- Trial name
- NCT01331304
- Testing
- Lithium, Quetiapine
- Where
- 11 sites in United States
- Volunteers
- 482 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Transcranial Magnetic Stimulation for Adolescent Depression
Major depression (or MDD) in adolescents is a major public health problem. MDD affects approximately 15% of adolescents; it is associated with impairment in social, family, and academic functioning, and it is a major risk factor…
- Trial name
- TMSAD (NCT01731678)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Depression, Postpartum
The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression
The proposed study aims to establish the feasibility of light therapy for postpartum depression delivered via Re-Timer, demonstrate its preliminary efficacy, and illuminate relationships between circadian shifts and mood changes…
- Trial name
- NCT02769858
- Testing
- Light therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan
Bipolar Disorder, Alcohol Use Disorder
Ondansetron for Bipolar Disorder and Alcohol Use Disorders
The purpose of the study is to determine if ondansetron, as an add-on therapy, is associated with reduced depressive symptoms and alcohol use in outpatients with bipolar disorder (BPD), cyclothymic disorder, schizoaffective…
- Conditions
- Bipolar Disorder, Alcohol Use Disorder, Dual Diagnosis
- Trial name
- NCT02082678
- Testing
- Ondansetron
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major
A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of Seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia…
- Trial name
- NCT04532749
- Testing
- Seltorexant
- Where
- 80 sites in United States, Argentina and 8 more
- Volunteers
- 212 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.